Smoking CessationSmokCessdTMSNCT03264313
Deep Transcranial Magnetic Stimulation (dTMS) to Induce Smoking Cessation
A study testing Deep Transcranial Magnetic Stimulation in people with Smoking Cessation and Transcranial Magnetic Stimulation, run by University of Sao Paulo General Hospital at 1 site in Brazil.
Trial summary
The purpose of this study is to evaluate the efficacy and safety of dTMS used as a tool for the smoking cessation; therefore, the subjects will be randomized to be treated on the active group or to receive placebo stimulation. Read more about this study
- Who is it for?
- Ages 22 to 70 years
- Conditions the study is for
- Smoking Cessation, Transcranial Magnetic Stimulation
- What is being tested?
- Deep Transcranial Magnetic Stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteBrazil
- Study dates
- 16 Jan 2017to Jan 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Current heavy (> 10 cigarettes / day) and chronic smokers (who have smoked for more than 1 year, with no abstinence greater than 3 months during the past year);
- Motivated to quit smoking;
- Capable to receive TMS treatment (satisfactory answers at the Safety Questionnaire for Transcranial Magnetic Stimulation);
- Consent report signed by the study participant.
Who cannot join
- Using nicotine replacement therapy or drugs to aid in smoking cessation (eg Bup, etc.) or dealing with behavioral therapy for smoking cessation.
- Functional or cognitive disorder, diagnosis according to DSM-5.
- Psychiatric Disorder active in the last year, according to DSM-5 (Axis I). Exception to depressive and anxious disorders, provided that in a stable condition.
- Substance or drug abuse or dependency in the current or in the last year prior to selection.
- Subjects who smoke any other type of tobacco or substances.
- Subjects with a high risk of violence or suicide assessed during the interview.
Show all 20Show fewer
- Subjects suffering from any physical instability such as high blood pressure (> 150 mmHg systolic / diastolic> 110 mmHg) or acute or unstable heart disease.
- History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT).
- Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or history of significant head injury or trauma with loss of consciousness for > 5 minutes.
- History of any metal in the head (outside the mouth).
- Metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps.
- Individuals with a significant neurological disorder or insult;
- Subjects suffering from frequent and severe migraine headaches.
- Subjects suffering from significant hearing loss.
- Subjects taking pro-convulsant medications (e.g., antipsychotic medications).
- Previous treatment with TMS.
- Subjects who cannot communicate reliably with the investigator or who are not likely to cope with the requirements of the experiment.
- Participation in a clinical trial within the last 30 days before the beginning of this clinical trial or similar participation in another clinical trial.
- Known or suspected pregnancy or lactation.
- Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.
Trial locations and contacts
1 site in 1 country.
Brazil1 site, 1 recruiting
- Recruiting
Incor - Instituto do Coração do HCFMUSP
São Paulo, 05403900
Bellini, 00551132571697, biancabellini@yahoo.com.br
About this study
Official title: A Prospective, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of the Use of Deep Transcranial Magnetic Stimulation (dTMS) on Smoking Cessation.
The purpose of this study is to evaluate the efficacy and safety of dTMS used as a tool for the smoking cessation; therefore, the subjects will be randomized to be treated on the active group or to receive placebo stimulation.
Read the detailed description
Smoking is the leading cause of preventable deaths in the world. Tobacco use causes more than 5 million deaths per year worldwide.
Among interventions methods that have been found to be effective, the medications are the most promising, using drugs such as Varenicline and Bupropion. Nicotine replacement therapy (NRT) shows results in combination to these drugs.
Alternative approaches to smoking cessation such as acupuncture, hypnosis, smokeless tobacco, electronic cigarettes are not legitimated smoking cessation tools; given that scientific studies showed no difference between these methods and placebo, or yet no rigorous peer-reviewed studies have been conducted.
On the neuromodulation field, Repetitive Transcranial Magnetic Stimulation (rTMS) appears as a new possibility to treat this serious condition.
The rTMS is a non-invasive method of stimulating cortical neurons. Repetitive TMS has been tested as a treatment of various neuropsychiatric disorders associated with cortical excitability disfunctions.
Several lines of evidence suggest that rTMS over the prefrontal cortex (PFC) can affect processes involved in nicotine addiction. First, animal studies demonstrated that rTMS to the frontal regions of rats enhanced release of dopamine in the hippocampus and NAc . Moreover, high-frequency rTMS of the human prefrontal cortex (PFC) has been shown to induce dopamine release in the caudate nucleus. Hence, it has been suggested that high-frequency rTMS may be useful in disorders associated with subcortical dopamine dysfunction, such as addiction.
Several human studies have begun to evaluate the effects of rTMS protocols applied to the PFC on drug craving and consumption in nicotine. Johann and colleagues reported decreased levels of tobacco craving after single rTMS session over the left dorsolateral prefrontal cortex (DLPFC). In addition, a single session of rTMS over the right DLPFC can reduce cocaine craving. Eichhammer and colleagues in a cross-over, double-blind, placebo-controlled study demonstrated a reduction in cigarette consumption (measured 6 hours following the treatment) but craving levels remained unchanged after two rTMS sessions over the left DLPFC. Amiaz and collegues found that 10 days of high-frequency rTMS over the DLPFC reduced cigarette consumption and nicotine dependence. In addition, the rTMS blocked craving induced by smoking cues. However, the effect tended to dissipate after the 10 daily sessions and the reduction in cigarette consumption was not significant 6 months after treatment termination. Moreover, only 10% among those who responded to the treatment had totally quit smoking. Li et al treated subjects with real high-frequency rTMS or sham TMS over the DLPFC in two visits with 1 week between visits. The participants received cue exposure before and after rTMS. Stimulation of the left DLFPC with real rTMS reduced craving significantly from baseline. When compared with neutral cue craving, the effect of real TMS on cue craving was significantly greater than the effect of sham TMS. Rudction in subjective craving induced by TMS correlated positively with higher Fagerström Test for Nicotine Dependence score and more cigarettes smoked per day. These four studies demonstrate that high-frequency rTMS of the DLPFC can attenuate nicotine consumption and craving. However, the significance and duration of these effects are limited and further investigation is required to identify the appropriate stimulation parameters and targets needed to enhance the effectiveness of such treatment.
One possible reason for these partial effects on nicotine consumption might be the superficial magnetic stimulation induced by the figure-8 coil, which does not reach into the deep layers of the cortex. It is known that nicotine addiction involves various areas of the brain reward system. Most of them are deeper than the superficial layers of the cortex, like the anterior cingulated, orbitofrontal cortex, nucleus accumbens, and amygdala.
Another area of interest which was not stimulated using the superficial rTMS is the insula. A recent study explored the role of insula damage in addiction. In a retrospective design, assessing changes in cigarette smoking after brain damage, results revealed that smokers with brain damage involving the insula were significantly more likely to undergo a disruption of smoking addiction than smokers with brain damage not involving the insula. This finding is consistent with the crucial role of the insula in cravings for food, cocaine and cigarettes, as reported by neuroimaging studies, and with the role of the insula in processes related to decision-making. Therefore stimulating the insula and the deeper layers of the lateral PFC could be substantially more effective in treating nicotine addiction.
Deep Transcranial Magnetic Stimulation (dTMS) is a new form of rTMS which allows direct stimulation of deeper neuronal pathways than standard rTMS using the Brainsway's new H-coils. In this study we will apply the dTMS using the H-ADD, which is designed to reach deeper brain areas related to the control of motivation, reward and pleasure, specifically, fibers connecting the DLPFC and the insula.
Given these theoretical, animal and preliminary human data, we hypothesized that a course of deep high-frequency, using a specific coil for deep stimulation (H-ADD) over the right and left lateral PFC and insula, may reduce impulsivity, nicotine dependence and craving for cigarettes in response to smoking-related cues.
- Being tested
- Deep Transcranial Magnetic Stimulation
- Keywords
- tobacco, Smoking Cessation, TMS, Neuromodulation, transcranial magnetic stimulation
- Medical subject headings
- Smoking Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Deep Transcranial Magnetic StimulationDevice
Also called dTMS
Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
| Study group | Role | What they receive |
|---|---|---|
| dTMS active | Active comparator | patients undergoing of dTMS real Receives: Device: Deep Transcranial Magnetic Stimulation |
| dTMS Sham | Sham comparator | patients undergoing to placebo dTMS Receives: Device: Deep Transcranial Magnetic Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Decrease on Monoximetry level
The researchers will perform the measurement of the rate of expired carbon monoxide through a monoximeter.
Measured: before each session at phase 1 (6 weeks = sessions from 1 to 18)
Secondary outcomes (1)
Changes on Cotinine blood level
The test uses a device that measures the levels of cotinine through a drop of blood obtained from a slight bite on the tip of the participant's finger.
Measured: at session 1 and after session 18 (6 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Aug 2017
- Study start16 Jan 2017
- Primary completionJan 2019 (estimated)
- Study completionJan 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Smoking CessationStudies of the same condition, open and under way.
- More trials run by University of Sao Paulo General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Manoel Jacobsen Teixeira, University of Sao Paulo General Hospital
- Investigators
- Marco A Marcolin, PhD, Study chair, University of Sao Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03264313
- Sponsor's protocol ID
- 35068014400000068
- Acronym
- SmokCessdTMS
- Status last verified
- Aug 2017
- First submitted
- 16 Aug 2017
- Last updated
- 5 Sep 2017
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Scholz JR, Bellini BB, Ziotti SDV, Abe TO, Arnaut D, Alberto RL, Marcolin MA, Tonstad S. Cue-Restricted Smoking as a behavioral adjunct for smoking cessation: Observational sub-analysis of a randomized trial of deep transcranial magnetic stimulation. Tob Prev Cessat. 2025 Oct 3;11. doi: 10.18332/tpc/209189. eCollection 2025.
PubMed 41048875
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of the Use of Deep Transcranial Magnetic Stimulation (dTMS) on Smoking Cessation.
- ClinicalTrials.gov ID
- NCT03264313
- Acronym / sponsor ID
- SmokCessdTMS / 35068014400000068
- Keywords
- tobacco, Smoking Cessation, TMS, Neuromodulation, transcranial magnetic stimulation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of Sao Paulo General HospitalUniversity, hospital or other
- Study start
- 16 Jan 2017 (actual)
- Primary completion
- Jan 2019 (estimated)
- Study completion
- Jan 2020 (estimated)
- First posted
- 29 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the efficacy and safety of dTMS used as a tool for the smoking cessation; therefore, the subjects will be randomized to be treated on the active group or to receive placebo stimulation.
Detailed description
Smoking is the leading cause of preventable deaths in the world. Tobacco use causes more than 5 million deaths per year worldwide.
Among interventions methods that have been found to be effective, the medications are the most promising, using drugs such as Varenicline and Bupropion. Nicotine replacement therapy (NRT) shows results in combination to these drugs.
Alternative approaches to smoking cessation such as acupuncture, hypnosis, smokeless tobacco, electronic cigarettes are not legitimated smoking cessation tools; given that scientific studies showed no difference between these methods and placebo, or yet no rigorous peer-reviewed studies have been conducted.
On the neuromodulation field, Repetitive Transcranial Magnetic Stimulation (rTMS) appears as a new possibility to treat this serious condition.
The rTMS is a non-invasive method of stimulating cortical neurons. Repetitive TMS has been tested as a treatment of various neuropsychiatric disorders associated with cortical excitability disfunctions.
Several lines of evidence suggest that rTMS over the prefrontal cortex (PFC) can affect processes involved in nicotine addiction. First, animal studies demonstrated that rTMS to the frontal regions of rats enhanced release of dopamine in the hippocampus and NAc . Moreover, high-frequency rTMS of the human prefrontal cortex (PFC) has been shown to induce dopamine release in the caudate nucleus. Hence, it has been suggested that high-frequency rTMS may be useful in disorders associated with subcortical dopamine dysfunction, such as addiction.
Several human studies have begun to evaluate the effects of rTMS protocols applied to the PFC on drug craving and consumption in nicotine. Johann and colleagues reported decreased levels of tobacco craving after single rTMS session over the left dorsolateral prefrontal cortex (DLPFC). In addition, a single session of rTMS over the right DLPFC can reduce cocaine craving. Eichhammer and colleagues in a cross-over, double-blind, placebo-controlled study demonstrated a reduction in cigarette consumption (measured 6 hours following the treatment) but craving levels remained unchanged after two rTMS sessions over the left DLPFC. Amiaz and collegues found that 10 days of high-frequency rTMS over the DLPFC reduced cigarette consumption and nicotine dependence. In addition, the rTMS blocked craving induced by smoking cues. However, the effect tended to dissipate after the 10 daily sessions and the reduction in cigarette consumption was not significant 6 months after treatment termination. Moreover, only 10% among those who responded to the treatment had totally quit smoking. Li et al treated subjects with real high-frequency rTMS or sham TMS over the DLPFC in two visits with 1 week between visits. The participants received cue exposure before and after rTMS. Stimulation of the left DLFPC with real rTMS reduced craving significantly from baseline. When compared with neutral cue craving, the effect of real TMS on cue craving was significantly greater than the effect of sham TMS. Rudction in subjective craving induced by TMS correlated positively with higher Fagerström Test for Nicotine Dependence score and more cigarettes smoked per day. These four studies demonstrate that high-frequency rTMS of the DLPFC can attenuate nicotine consumption and craving. However, the significance and duration of these effects are limited and further investigation is required to identify the appropriate stimulation parameters and targets needed to enhance the effectiveness of such treatment.
One possible reason for these partial effects on nicotine consumption might be the superficial magnetic stimulation induced by the figure-8 coil, which does not reach into the deep layers of the cortex. It is known that nicotine addiction involves various areas of the brain reward system. Most of them are deeper than the superficial layers of the cortex, like the anterior cingulated, orbitofrontal cortex, nucleus accumbens, and amygdala.
Another area of interest which was not stimulated using the superficial rTMS is the insula. A recent study explored the role of insula damage in addiction. In a retrospective design, assessing changes in cigarette smoking after brain damage, results revealed that smokers with brain damage involving the insula were significantly more likely to undergo a disruption of smoking addiction than smokers with brain damage not involving the insula. This finding is consistent with the crucial role of the insula in cravings for food, cocaine and cigarettes, as reported by neuroimaging studies, and with the role of the insula in processes related to decision-making. Therefore stimulating the insula and the deeper layers of the lateral PFC could be substantially more effective in treating nicotine addiction.
Deep Transcranial Magnetic Stimulation (dTMS) is a new form of rTMS which allows direct stimulation of deeper neuronal pathways than standard rTMS using the Brainsway's new H-coils. In this study we will apply the dTMS using the H-ADD, which is designed to reach deeper brain areas related to the control of motivation, reward and pleasure, specifically, fibers connecting the DLPFC and the insula.
Given these theoretical, animal and preliminary human data, we hypothesized that a course of deep high-frequency, using a specific coil for deep stimulation (H-ADD) over the right and left lateral PFC and insula, may reduce impulsivity, nicotine dependence and craving for cigarettes in response to smoking-related cues.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| dTMS active | Active comparator | Device: Deep Transcranial Magnetic Stimulationpatients undergoing of dTMS real |
| dTMS Sham | Sham comparator | Device: Deep Transcranial Magnetic Stimulationpatients undergoing to placebo dTMS |
Who may qualify
- Ages
- 22 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Current heavy (> 10 cigarettes / day) and chronic smokers (who have smoked for more than 1 year, with no abstinence greater than 3 months during the past year);
- Motivated to quit smoking;
- Capable to receive TMS treatment (satisfactory answers at the Safety Questionnaire for Transcranial Magnetic Stimulation);
- Consent report signed by the study participant.
Key exclusion criteria (20 listed)
- Using nicotine replacement therapy or drugs to aid in smoking cessation (eg Bup, etc.) or dealing with behavioral therapy for smoking cessation.
- Functional or cognitive disorder, diagnosis according to DSM-5.
- Psychiatric Disorder active in the last year, according to DSM-5 (Axis I). Exception to depressive and anxious disorders, provided that in a stable condition.
- Substance or drug abuse or dependency in the current or in the last year prior to selection.
- Subjects who smoke any other type of tobacco or substances.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Deep Transcranial Magnetic StimulationAlso: dTMSPatients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation | Device | dTMS Sham, dTMS active |
Primary outcome
Decrease on Monoximetry level
Time frame: before each session at phase 1 (6 weeks = sessions from 1 to 18)
The researchers will perform the measurement of the rate of expired carbon monoxide through a monoximeter.
1 secondary outcome
Changes on Cotinine blood level
Time frame: at session 1 and after session 18 (6 weeks)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2017.
- Derived from this study: PubMed 41048875Scholz JR, Bellini BB, Ziotti SDV, Abe TO, Arnaut D, Alberto RL, Marcolin MA, Tonstad S. Cue-Restricted Smoking as a behavioral adjunct for smoking cessation: Observational sub-analysis of a randomized trial of deep transcranial magnetic stimulation. Tob Prev Cessat. 2025 Oct 3;11. doi: 10.18332/tpc/209189. eCollection 2025.
- Individual participant dataSharing planned: No
Related trials for Smoking Cessation
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
Recruiting
Social Media Support Groups for Adolescent Vaping Cessation
Vaping, Vaping Cessation
Not yet recruiting
Impacto 2.0: Mobile Smoking Cessation Across Texas
Cigarette Smoking, Smoking Cessation
Active, not recruitingPhase 4
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marco A Marcolin, PhD study chair
University of Sao Paulo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Deep Transcranial Magnetic Stimulation in people with Smoking Cessation and Transcranial Magnetic Stimulation, run by University of Sao Paulo General Hospital at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Bianca B Bellini, MD (00551132571697, biancabellini@yahoo.com.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Decrease on Monoximetry level (time frame: before each session at phase 1 (6 weeks = sessions from 1 to 18)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03264313, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2017.